Categories
Nevin Manimala Statistics

Relationship between DHX15 expression and survival prognosis in colorectal cancer

Rev Esp Enferm Dig. 2022 Sep 30. doi: 10.17235/reed.2022.8838/2022. Online ahead of print.

ABSTRACT

Objective To explore the relationship between the expression of DEAH-box RNA helicase 15 (DHX15) in colorectal cancer (CRC), its clinical pathological features and survival prognosis. Method DHX15 expression data with clinic pathological features from the Cancer Gene Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), were statistically analyzed for the association between DHX15 expression and overall survival of CRC. The expression of DHX15 was performed by immunohistochemical staining (IHC) using tumor and the adjacent normal tissues mounted in tissue microarrays. The significance of DHX15 expression in predicting the survival and prognosis of CRC were analyzed using Kaplan-Meier method, Univariate and Multivariate Cox regression analysis. Results Low expression of DHX15 mRNA and DHX15 protein in CRC were both negative factors for survival prognosis. Overall survival of patients with low-expression of DHX15 was significantly lower (χ2=8.452, p=0.004) by Kaplan-Meier evaluation. Low expression of DHX15 in CRC tissues was correlated with distal lymph node metastasis (χ²=7.120, p=0.008), TNM stage (χ²=3.935, p=0.047) and disease recurrence (χ²=9.524, p=0.002) of CRC patients. Low expression of DHX15, (HR=4.012, 95%CI: 1.462~11.013, p=0.007), late TNM stage (HR=0.067, 95%CI: 0.029~0.156, p<0.001) and recurrence (HR=0.008, 95%CI: 0.002~0.034, p<0.001) were risk factors related to the prognosis of CRC patients by Univariate Cox regression analysis. Conclusion Our findings reveal a key role for DHX15 in the progress of CRC metastasis and recurrence. DHX15 may be a potential biomarker for CRC targeted therapy.

PMID:36177832 | DOI:10.17235/reed.2022.8838/2022

By Nevin Manimala

Portfolio Website for Nevin Manimala